Technologies That Are Revolutionizing Baseball

With the 2020 World-Series around the corner, it’s important to reflect on baseball’s long history in this country. This will be the 116th edition of the World Series, which highlights just how long the sport has managed to stay relevant and loved by its fans. Despite being an old sport, there are several new advances and technologies introduced to the game that have modernized and changed the baseball experience.

One baseball technology that has impacted the overall player experience is Biotracking. Biotracking is where biomonitors record and measure different physical data. The wristband monitor tracks vital signs and physical stress during sleep, play, rest, and recovery. This data is useful for adjusting workouts, pitching motions, running style, and sleep cycles to the player’s individual needs.

Baseball technologies have also changed audience experience through VR systems. Virtual reality has expanded baseball’s audience by allowing fans to be in the game. Some teams like the San Francisco Giants have in-stadium VR, and the Chicago Cubs also had VR 360 viewing of the World Series celebration in 2016.

In addition to impacting the overall player and audience experience, there are also several technologies in use that focus on body mechanics and data gathering. Examples of technologies focused on body mechanics are:

  • The K Vest: a technology that places sensors on a batter’s upper torso, pelvis, and leading arm and hand. It captures motion and provides a detailed analysis of swing efficiency.  It is currently used by 21 different MLB teams, in addition to separate academies and individual players.

  • The SwingTracker is a technology used by 15 different MLB teams. It is a sensor that is attached to the knob of a bat and transmits data about angles, planes, and velocity. Using this data, a 3D model of a player’s swing can be created.

  • KinaTrax is a technological system consisting of 8 to 16 high-speed synchronized video cameras. These are installed along the first and third baselines, and they capture every movement of the pitcher and hitter. The system then provides 3D rotational and positional data for the movement.

  • The Edgertronic SC1 is a high-speed video camera capable of capturing up to 22,000 frames per second. Teams use the slow-motion visuals to see how a pitcher’s grip changes as he releases a ball, or how subtle adjustments in finger position affect ball rotation. Edgertronic is currently used by most MLB teams.

  • Rapsodo is a radar and camera combination that is situated on the ground between the mound and the home plate. The radar and camera combination results in data on ball speed, velocity, launch angle, and spin for pitchers and batters. This technology provides a ball-focused pitch analysis that can allow coaches and players to highlight areas for development.

  • Baseball has established itself as a timeless sport through its everlasting fanbase. Thanks to these technology advances, the sport will continue to modernize along with its audience.


Students: How to Effectively Communicate Science

When I first started working at Emory as a postdoctoral fellow, I was very excited to perform research at such a prestigious institution. Besides working in a lab, I was always passionate about science communication and soon started searching for opportunities to pursue my interest. Not too long after, I came across the Office of Technology Transfer (OTT) Marketing and Communications internship through word of mouth from previous interns. I quickly got in touch with the team to learn more and eventually applied and started.

Being a researcher, I was comfortable with scientific topics in my area of expertise, but I was eager to learn more about the breadth of research conducted at Emory. As a writer for the OTT blog and website, I had the opportunity to speak with Emory researchers across different disciplines – from immunology and oncology to plant research and beyond. I learned more about their work and goals, as well as the possible future impact of their discoveries on our lives. I also found out more about the licensing process, which was an entirely new field to me. I learned how the OTT helps researchers maximize the impact of their work and also protect their intellectual property.

During my time at the OTT, I had the unique opportunity to write about science in a way that is accessible to a broader audience. For most scientists, it becomes second nature to write complex scientific papers and speak in jargon and technical terms. However, it is important to also develop the ability to capture the main points of our work and explain it in a way that simplifies it, but still elevates its importance. Writing for the Simple Science blog series, I put myself in the reader’s shoes and practiced communicating science in a simple but engaging way.

This experience at the OTT solidified my decision to pursue science writing as a full-time job. I started applying for scientific writer positions and soon started interviewing. I can honestly say that my internship at the OTT was one of the most impactful lines on my resume and truly made me a better candidate. Not only did it give me important hands-on experience with writing, but it also helped me appreciate the impact of research in society and expand my horizons. I am now in a new role where I am writing about science full-time, and I see the benefits of my OTT experience every day in my work.

I am forever grateful to the OTT and the Marketing & Communications team in particular. Everyone was very helpful and easy to work with, making me feel at ease as a new intern. I truly believe this internship is a unique experience for students and trainees at all levels, whether in college, grad school or even during a postdoc. I wish all the best for the new cohort of interns and I am looking forward to all the amazing work that will come out of the OTT in the future!

— Vicky Kanta

Students: Learning to Write About Science

As a media studies major with an interest in writing and communications, I jumped at the chance to intern with the Office of Tech Transfer in the marketing department throughout my senior year.

From prior work experiences at magazines and web publications, I had quickly become familiar with the ins and outs of interviewing subjects, creating compelling social media content, and telling a good story. During my first few weeks at the Office of Technology transfer, I quickly realized that there was one critical function I was less familiar with: understanding and talking fluently about science.

My last, and only, academic exposure to the field of science was an astronomy class my freshman year, but suddenly I was thrust into the world of nanotechnology, medication adherence scales, liver disease, and more, introduced to me via PhD graduates and professors who are at the top of their respective fields.

Though I was intimidated at first, I soon realized that I had been given a really unique opportunity to learn more about the unmatched scientific innovation that occurs behind the scenes at Emory from the eyes of an outsider. Perhaps most importantly, I realized that I had a unique responsibility to share these ideas, inventions, and innovations in a way that someone like myself–with little to no background in science–could understand and engage with.

I took that responsibility seriously, and I enjoyed writing pieces on topics as varied as in-depth profiles of featured innovations at Emory to tongue-in-cheek social media posts about fun and unique patents to use at Christmas time.

While I never quite fully understood some of the more abstract scientific topics that I explored during my time at OTT, I left with a much stronger knowledge of scientific advancement and the licensing process as a whole. I have no doubt that my newfound background in science and tech writing will prove invaluable as I pursue a career that allows me to communicate widely with audiences across a range of subjects. (Though I think I’ll steer clear of nanotech–that never really clicked!) In all seriousness, my internship with OTT was one of my favorite experiences at Emory both because of the things it taught me, and for all of the things it didn’t.

— Presley West

Wearables in Clinical Trials: Exciting Developments and Lingering Concerns

The use of wearable devices has skyrocketed over the past few years, with approximately 21% of Americans reporting regular use of a smart watch or wearable fitness tracker. Wearables are a great source of health-related data, which can even be streamed remotely in real time. Nowadays, smart wearable devices incorporate more sensors than ever – heart rate, oxygen saturation, even electrocardiograms, along with fitness and sleep information. Their potential advantages in clinical trial settings have not gone unnoticed. According to, there are approximately 950 trials that are using wearable devices, with over 300 of them successfully completed. However, this still only accounts for <2% of all trials, even though more studies could potentially benefit from their use.

One of the biggest issues in clinical trials is patient adherence to protocol, especially when there is extensive data collection required at home. This can be very demanding for participants and may discourage participation. Wearables can serve two roles in that domain, by delivering medication reminders and by collecting information in a continuous manner without the patient’s input. Importantly, since a large portion of the study can be conducted in the comfort of the participant’s home, this should lower participant dropout rates.

Wearable devices offer clear advantages in terms of data quantity and quality. Clinical trials are often conducted across different centers, sometimes spanning multiple continents. The use of the same wearable device type across sites will help with data consistency regardless of geographic location, especially if proper device usage training is provided. At-home data collection is also highly beneficial to researchers, since it results in real-life numbers that are consistent with the patients’ everyday activities. Furthermore, the increasing use of artificial intelligence (AI) in clinical trial data analysis will facilitate important pattern detection in large datasets collected from these devices.

Despite the large growth in wearable incorporation in clinical trials, there are still some legitimate concerns regarding regulations. The Clinical Trials Transformation Initiative has an extensive set of recommendations for the use of mobile technologies in clinical trials. They emphasize that devices themselves do not need to be approved by the Food and Drug Administration (FDA) to be used in clinical trials, but they do need to “verify and validate the appropriateness of the selected mobile technology.” The main problem here lies with the proprietary nature of the algorithms that these devices use, which may not allow researchers to thoroughly assess the accuracy of their sensors. In addition, many wearable manufacturers do not allow direct access to the raw data and give “black box” descriptions of the acquisition method and processing that takes place. The lack of data standards will likely slow the adoption of such devices in clinical trials.

Another issue regarding wearable use in clinical trials has to do with data ownership. All patient data collected during clinical trials fall under the Health Insurance Portability and Accountability Act (HIPAA), which regulates how protected health information can be used and shared. Consumer-grade devices are not regulated in the same way as medical devices, therefore many of the rules governing data protection are up to the manufacturers. Although many wearable manufacturing companies are working to support HIPAA compliance, there are still various privacy and data security concerns.

The innovation and potential that accompanies the use of wearables in clinical research is undeniable. However, there is still room for improvement to ensure a safe and reliable incorporation that benefits scientists, patients and society as a whole. Since this field is still fairly new, we can expect some drastic developments in the immediate future.

—  Vicky Kanta

Outside the Office: Volunteering with Professional Organizations

Several employees at the Office of Technology Transfer extend their expertise in the technology industry to outside professional organizations.

Among these employees are Laura Fritts, Director of Patent and License Strategy and Chief Intellectual Property Officer; Kimberly Dunn, Compliance Associate; Linda Kesselring, Operations Director; Kevin Lei, Director of Faculty and Start-Up Services; Patrick Reynolds, Assistant Director of Faculty and Start-up Services; Quentin Thomas, Marketing Manager; and Sarah Wilkening, Licensing Associate.

The majority of the above OTT employees volunteer with the Association of University Technology Managers (AUTM). AUTM is a nonprofit organization that supports individuals involved in technology transfer through education, professional development, and advocacy, among other activities. Through these methods, the organization provides knowledge of technology transfer beyond Emory and forges connections between members, which is why many employees opted to join.

Each involved OTT member contributes to AUTM in a different capacity, ranging from assisting with marketing to hosting instructional webinars. For example, while Fritts serves on the AUTM Public Policy Legal team, Dunn previously served on the Distance Learning Committee organizing speakers for AUTM-hosted webinars and was Chair of the Intellectual Property Portfolio Management Committee. As chair, Dunn helped develop and manage an annual course for three years before recently joining AUTM’s TOOLs Committee.

Having been an AUTM member for over 20 years, Kesselring currently serves as chair of the website committee. As chair, she works with AUTM staff focused on marketing and communications and organizes work, activities, and conference calls to “meet objectives for the AUTM website.” This is done through tasks like supporting the website’s redesign and providing regular statistics.

Reynolds chairs AUTM’s Better World Project committee, a group that selects stories submitted by technology transfer offices about how their technologies “make the world a better place.”

“It’s easy to get in the cycle of only knowing what is happening in your own office,” he said. “The Better World Project allows me to see the great work that institutions and [technology transfer offices] around the world are doing.”

Thomas, another AUTM volunteer, occasionally serves as a presenter on Annual Meeting webinar sessions and recently left the Marketing Course Committee after working with this group for three years. He noted that his work with AUTM increases exposure of Emory’s OTT office and fuels additional opportunities, while also allowing him to learn new skills and gain knowledge from colleagues at other institutions.

In addition to those who volunteer with AUTM, several OTT employees cite benefits from volunteering with outside organizations. Lei volunteers with Certified Licensing Professional (CLP), Inc. as a member of The CLP Exam Development and Maintenance Committee. The CLP program certifies professionals that demonstrate experience and proficiency in the licensing and commercialization of intellectual property after they take and pass a 150 multiple choice question exam. When the organization recruited volunteers to revise exam questions in 2019, Lei took this opportunity.

“I thought it would be important to be involved and help maintain the high standard of the CLP program, because it takes dedicated volunteers to develop a quality certification program,” he said.

Wilkening primarily volunteers with the Patent Agents of Georgia, an organization she co-founded under the Georgia Intellectual Property Alliance. This group aims to foster community among Georgia’s past, present, and future patent agents and coordinates networking events for “science-lovers that want to stay at the frontlines of research without having to do the research.”

“I wish I would have known about this career path earlier in my life … Being a patent agent can be a rewarding career opportunity,” she said. “This organization has brought together technology transfer and patent professionals from all over Georgia, and I have had the honor to help branch those networking opportunities.”

Fritts has volunteered as a lawyer with the Executive Committee for Atlanta’s IP Inn of Court and the Advisory Board for the United States Patent and Trademark Office (USPTO) Georgia PATENTS. As a volunteer, she has helped inventors file patent applications, saying, “The benefits to the organizations, my office, and me personally far outweigh the burden of the work.”

Dunn also volunteered with the Georgia Association of Paralegals’s Atlanta Legal Aid Society. With this organization, she assisted domestic violence victims in filing appropriate documents involving scenarios like temporary restraining orders and coordinating temporary housing. She listed obtaining a “diverse network of knowledge and experience” among several benefits she received from volunteering.

“Volunteering is like continuing education: we constantly learn something new,” she explained. “The most important benefit is the feeling of being a part of something bigger than yourself.”

What is Telemedicine?

Telemedicine is the use of available telecommunications technologies to diagnose and provide care to patients from a remote location. Although frequently mentioned in the news lately due to COVID-19, telemedicine is a field that has been around for more than 50 years.

The need to treat patients without seeing them in person arose mostly because of people in rural areas, who were unable to travel long distances to see a doctor or go to a hospital. To solve this issue, doctors would talk to patients on the phone and even use the telegraph to send and receive medical information. Nowadays, modern video-conferencing is widely used for telemedicine, providing an easy and convenient way to share information with providers. Since file sharing is easier than ever, doctors can electronically send their patients their lab results, X-Rays, and other types of diagnostic information. Furthermore, doctors can share patient records with each other, enabling them to provide better collaborative care to their patients.

Since the use of smart devices has increased in the past few years, many doctors now have remote access to important health information, such as their heart rate, activity levels and even their blood pressure. That way patients can receive medical advice from the comfort of their home, without unnecessary travel and long wait times at doctor’s offices. Telemedicine helps doctors with office-related costs while also saving them precious time and allowing for more appointments. As evidenced during this pandemic, an additional benefit of telemedicine is the reduced risk of exposure to contagious diseases that are frequently found in hospitals and doctor’s offices, therefore protecting both patients and medical personnel.

The telemedicine industry is rapidly growing, with more and more tech companies creating HIPAA-compliant video platforms and e-health environments. With the inevitable future developments in the medical device sector, it is very likely that telemedicine is here to stay as a regular part of medical care.

More resources on telemedicine:

Emory Female Inventors Revisited

The Emory community is proud to have some of the most cutting-edge research teams led by women. Female scientists at Emory are responsible for a variety of innovative discoveries in biomedical sciences and technology. Some of their inventions have had profound positive impact on the scientific community and society as a whole. In this article, we are honoring five of Emory’s female inventors and their work. Check out our previous post on Emory Female Inventors.

Cassandra Quave is an Assistant Professor of Dermatology at the School of Medicine and the Center for the Study of Human Health. She is a medical ethnobotanist, studying the medicinal properties of novel plant compounds. One of the biggest issues in modern medicine is the existence of bacterial strains that do not respond to most known antibiotics or drugs. To tackle this issue, Quave is looking for new plant-derived molecules that can help with the treatment of antibiotic-resistant infections. Her team discovered compounds in the sweet chestnut and Brazilian pepper trees that can combat methicillin-resistant Staphylococcus aureus (MRSA), one of the most common and dangerous healthcare related infections. These extracts are a safe and effective way to mitigate MRSA symptoms and halt disease progression. Her important work has been prominently featured in the New York Times and NPR.

Hyunsuk Shim is a Professor at the Department of Radiation Oncology and a Crocker Family Chair in Cancer Innovation. She is studying how certain molecules called chemokines and their receptors may participate in cancer metastasis and inflammation. Research has shown that one of these chemokines (CXCR4) is found in various types of cancer, such as breast and colon. Shim and her team developed new chemical molecules that effectively block CXCR4 and its receptor and can be used as safe anti-cancer therapeutics. However, Shim’s work doesn’t stop there: she is also interested in new imaging methods for diagnosis and risk assessment of brain tumors. To this end, she has developed a web-based application that utilizes imaging data to assist with tumor diagnosis and treatment planning. You can learn more about Shim’s innovative platform here.

Suephy Chen is Professor and Vice Chair of the Department of Dermatology and Director of the Dermatology Clinical and Outcomes Research Unit at Winship Cancer Institute. Her work is focused on skin diseases and their effects on society and patients’ quality of life. Skin diseases such as rosacea and scalp dermatitis can be debilitating for the patient, and their burden is often poorly assessed. As a solution, Chen has developed a variety of tools that help physicians assess the quality of life associated with these diseases. These instruments can help doctors and patients find the most effective treatments by rigorously measuring disease progression over time. Chen’s important work has led to many honors, including awards from the National Institutes of Health, the Dermatology Foundation and the Veterans Administration. Read more about Suephys work in one of our featured innovations here.

Malathy Shanmugam is an Associate Professor at the Department of Hematology and Medical Oncology. She is working on the development of new treatments for multiple myeloma, an aggressive form of plasma cancer that is highly drug resistant. Shanmugam’s work has led to the discovery of several small molecules that help potentiate the effect of existing therapies. These molecules target the glucose metabolism pathways of cancer cells, essentially “starving” them. Furthermore, Shanmugam’s team is studying how cancer metabolism can affect the probability of cancer metastasis, which may lead to more potential treatments. You can learn more about Shanmugam’s work here.

Chia-shi Wang is an Assistant Professor of Pediatrics at the Division of Pediatric Nephrology. Her research focuses on childhood nephrotic syndrome, a common kidney disease where protein is released in the urine and can lead to kidney injury. This disease requires extensive at-home monitoring, which can be difficult for patients. To assist with that, Wang has developed a mobile application that helps with nephrotic syndrome management. The app can track and analyze urine test strips and detect disease developments. Furthermore, patients can easily find educational resources and information on their condition. Wang’s work does not stop there, since she is also involved in clinical trials for new kidney disease treatments. Read about one of Chia-shi’s innovations in this technology brief.

Access to Experimental Drugs

Experimental drugs can be a lifeline for those with conditions for which conventional treatments are not working or readily available. At the same time, doctors and patients want to have confidence that they are making safe and informed choices when requesting the use of drugs that have not have fully completed the clinical trial process.  With many doctors turning to experimental treatments for COVID-19 patients, this topic has recently gained renewed attention. Two processes in particular: compassionate use and Right to Try, give patients with serious or terminal conditions the ability to gain access to treatments which have not received FDA approval. These treatments can be potentially lifesaving for those whom conventional treatment is either unavailable or not working.

Compassionate use, formally known as Expanded Access, allows patients access to experimental treatments with approval from their doctor, the FDA, and an Institutional Review Board (IRB). The patient must meet several criteria, including having a serious disease or condition for which no comparable satisfactory treatment is available and being unable to enroll in clinical trials for the drug. If patients decide to pursue compassionate use, they must first speak to their physician, who then files a request to both the FDA and IRB. Eligibility is granted by the FDA if the agency determines that both (1) the benefits of using the experimental treatment outweigh any risks and (2) that its use will not jeopardize ongoing clinical trials. The FDA must respond to such a request within thirty days, and approval has historically been granted in 99% of cases. Secondly, the use must be approved by a registered IRB. Only once both of these steps are complete is the patient allowed access to the drug.

In May 2018 Congress passed the Right to Try Act, establishing a second process for patients to gain access to experimental treatments. Under Right to Try, patients with life-threatening conditions no longer need the approval of the FDA and IRBs to gain access to certain experimental drugs. Those with a terminal illness can submit a request directly to the manufacturer of an experimental treatment with the consent of their doctor. They may then obtain the treatment if the manufacturer approves. Similar to with compassionate use, patients using the Right to Try process must have exhausted all available conventional treatments and be unable to participate in clinical trails involving the experimental drug. The medication must also have completed Phase 1 clinical trials, an additional requirement not present in the compassionate use process. Right to Try has proven controversial in the scientific community since its conception. Proponents claim it cuts red tape patients for terminally ill patients in obtaining treatment, but critics point to the lack of reporting requirements and say that Right to Try removes safeguards in the compassionate use process that ensure patient safety.

While compassionate use and Right to Try have different processes, the programs share several key limitations. Importantly, manufacturers have no obligation to provide experimental drugs under either process, and the FDA has no power to compel companies to do so. Many manufacturers are reluctant to provide patients access to experimental drugs due to concerns that adverse reactions could lead to negative publicity or interfere with the FDA approval process.  Additionally, insurance companies are under no obligation to cover experimental treatments. The fact that many patients must pay out-of-pocket for experimental treatments has led to a stratified system where low-income patients are unable to obtain experimental drugs.

Despite these constraints, both compassionate use and Right to Try continued to be utilized by doctors and patients across the country. Many individuals with severe or terminal illness can’t afford to wait the seven to twelve years it takes for drugs to be approved by the FDA. Through compassionate use and Right to Try, these patients with few options left get a renewed chance.

Introduction to Artificial Intelligence and Healthcare

The healthcare industry generates a lot of data. X-rays, pathology slides, patient vitals, clinical trial information; we have mountains of information accessible at the touch of a button. But it’s costly and time-inefficient for humans to manually pour over it. So what do we do with all of this data?

The field of intelligence (AI) allows not only to let us analyze all our data, but to find subtle and complex patterns in them. Machine learning algorithms are particularly responsible for these advancements. Engineers have developed software that’s able to look at a dataset, find relationships between a bunch of variables, and then make mathematical models that we can use to predict behaviors in the future or analyze other sources of data: images, patient records, etc.

What does that mean in the real world? Computer scientists can make systems that can analyze an image and detect a disease better than humans can. They can make programs that are able to predict the notoriously unpredictable process of how proteins fold, or even make drugs which are currently in human trials. Let’s learn a little more about how machine learning works, and see some of the current applications.

How machine learning systems work

Machine learning systems are complex algorithms. Algorithms are methods of “treating” data: a computer receives an input, some sort of data. The computer recognizes that data and sorts it. For example, let’s say I have a program that can tell me if the color of an animal I’m thinking about makes sense. if I type in the phrase “blue horse,” there might be something in the code that recognizes the word “blue” and the word “horse.” The code then might have some information about the colors a horse can be, and would have an instruction to compare “blue” with “horse.” If “blue” isn’t in the “horse” database, then the computer would have an instruction to tell me “No, horses can’t be blue.” To make it simple, algorithms are sets of instructions that do something with information we give it.

AI Flow Chart

A simple algorithm for calculating interest. Courtesy of Edraw.

They get way more complex than that example. Specific algorithms can take ridiculous amounts of data and look for statistical relationships between them. Machine learning systems are able to make new models by using what are called learning algorithms. There are a bunch of different types, but the most conceptually simple ones involve supervised learning. These learning algorithms are exposed to a “training set” of data with a bunch of examples with known “right answers” — for example, a bunch of CT scan images from patients whom we know have cancer or not. The algorithm “doesn’t know” which patients have the disease. It keeps changing the instructions inside of its algorithm to try to — if the computer sees a white spot in a patient’s liver, it says yes, but this turned out to be wrong, so the next time the computer doesn’t care about that spot when saying yes or no.

Do this a bunch of times, and eventually the algorithm learns what data points lead to the correct output: the machine learns. Over time, these algorithms get very accurate, and we can use them for specific applications.

Radiology and imaging

Image analysis is a very natural application of this sort of software. The cancer example above isn’t science fiction: Google’s already developed a system that’s able to detect breast cancer. A very recent study published information about a deep learning model that’s able to diagnose forms of common hip arthritis at an accuracy rivaling radiologists’ analysis.

But there are concerns about the current state of radiology AI and bringing these technologies to the clinic. Analyzing images is a very complex process, critics argue, and we don’t always know how these machine learning systems actually work. Although applications are rapidly developing, it’s clear that radiologists are still very necessary.

Breast Cancer Image

A picture of an image where an AI system found cancer in a human breast. Courtesy of Northwestern University via The New York Times.


Drug discovery

UK-based startup Exscientia became the first company to develop a small-molecule drug entirely designed by artificial intelligence. Small-molecule drugs are tiny chemicals that generally “stick” to proteins of interest. It is very hard to know what sort of molecules will stick and treat a disease and which ones won’t. The scientists at Exscientia use a learning algorithm that takes data from human-run tests to optimize the structure of the chemical they’re making, reducing the amount of time it takes to get a working drug. The compound, titled DSP-181 and targeted toward treating obsessive-compulsive disorder, is set to enter clinical trials in Japan soon.

Point-of-care solutions

AI doesn’t just help us make drugs; it can help us deliver them, too. Electronic health record systems are growing more and more. Nurses say that bureaucratic work cuts their time spent with patients by about 25 percent. Doctors report that less than half of their patients are what they’d describe as “highly engaged” in their course of care. Engineers are already developing systems that can not only manage data, but use electronic information to make predictions about how patients might comply with certain treatments.

From point-of-care solutions and radiology to drug discovery and beyond, it’s clear that artificial intelligence will play an increasingly large role in analyzing healthcare data in the future in ways both known and unknown to us now. New applications of machine learning systems are rapidly developing as engineers aim to create new machine learning algorithms that can analyze and find complex data. Used in tandem with the expertise of doctors, radiologists, and other healthcare professionals, these algorithm-based technologies are already modernizing our healthcare system and have the potential to improve public health on an even larger scale in the future.

Finding Emory Innovations to Build Your Company’s Product Pipeline

Emory has approximately 600 technologies available to license at any given time. In particular, Emory offers a variety of live science resources such as therapeutics, diagnostics, and research tools that are marketed by Emory OTT.  

However, finding new technologies available at a university can be time-consuming and potentially frustrating for startups and established companies alike. Below are simple ways to find and remain up-to-date with technologies coming from Emory University.

  1. Subscribe to TechFeed to receive email notifications about products: TechFeed is a notification system where users can sign up to receive emails about recently added technologies. It can be individually customized to get notifications based on what products you’re interested in and how frequently you want to be notified. 

  2. Use our Technology Listings page: To get an improved searching experience with more accurate results, use our Google-powered search option. Through this, you can find non-confidential summaries of available technologies. Alternatively, if you’re looking for something around a specific indication or topic, click on Keywords in our word cloud and Technology Categories to get a list of these technologies.

  3. Visit our Featured Innovations page: Using these articles, you can get more information about and see real-world applications of available technologies.

  4. Contact our knowledgeable Marketing Associate, Quentin Thomas: Reach out to Quentin via email to request a hand-picked selection of technologies related to your needs and areas of interest. Quentin also encourages interested parties to set up a face-to-face conversation with him so he can guide the path from there. 

  5. Subscribe to our RSS feed and follow us on Twitter @Emory OTT: By doing this, you can stay up-to-date with all of our new technologies as soon as they’re listed on the website.

Additionally, to find a one-stop shop to find technologies from Emory as well as universities worldwide, there are a number of third-party listing services available to search free of charge, including the Association of University Technology Managers (AUTM) Innovation Market (AIM).

Our goal as technology matchmakers is to simplify the process for industry colleagues to find our technologies. If you have any suggestions on how we can improve this process, please contact us.